当前位置： SCI文献检索 > EPIDEMIOLOGY AND INFECTION期刊下所有文献 > Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence.

Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence.

Abstract：

:In 2014, the Food and Drug Administration approved a new human papillomavirus 9-valent vaccine (9vHPV), targeting nine HPV types: HPV types 6, 11, 16, and 18, which are also targeted by the quadrivalent HPV vaccine (qHPV), plus five additional high cancer risk HPV types (HPV types 31, 33, 45, 52, and 58). The aim of the current study was to systematically retrieve, qualitatively and quantitatively pool, as well as critically appraise all available evidence on 9vHPV from randomized controlled trials (RCTs). We conducted a systematic review of the literature on 9vHPV efficacy, immunogenicity and safety, as well as a systematic search of registered, completed, and ongoing RCTs. We retrieved and screened 227 records for eligibility. A total of 10 publications reported on RCTs' results on 9vHPV and were included in the review. Sixteen RCTs on 9vHPV have been registered on RCT registries. There is evidence that 9vHPV generated a response to HPV types 6, 11, 16 and 18 that was non-inferior to qHPV. Vaccine efficacy against five additional HPV type-related diseases was directly assessed on females aged 16-26 years (risk reduction against high-grade cervical, vulvar or vaginal disease = 96·7%, 95% CI 80·9%-99·8%). Bridging efficacy was demonstrated for males and females aged 9-15 years and males aged 16-26 years (the lower bound of the 95% CIs of both the geometric mean titer ratio and difference in seroconversion rates meeting the criteria for non-inferiority for all HPV types). Overall, 9vHPV has been proved to be safe and well tolerated. Other RCTs addressed: 9vHPV co-administration with other vaccines, 9vHPV administration in subjects that previously received qHPV and 9vHPV efficacy in regimens containing fewer than three doses. The inclusion of additional HPV types in 9vHPV offers great potential to expand protection against HPV infection. However, the impact of 9vHPV on reducing the global burden of HPV-related disease will greatly depend on vaccine uptake, coverage, availability, and affordability.

journal_name

Epidemiol Infect

journal_title

Epidemiology and infection

authors

Signorelli C,Odone A,Ciorba V,Cella P,Audisio RA,Lombardi A,Mariani L,Mennini FS,Pecorelli S,Rezza G,Zuccotti GV,Peracino A

doi

10.1017/S0950268817000747

subject

Has Abstract

pub_date

2017-07-01 00:00:00

pages

1962-1982

issue

eissn

0950-2688

issn

1469-4409

pii

S0950268817000747

journal_volume

145

pub_type

杂志文章,评审

在线工具

Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence.